FY2025 EPS Estimates for DNTH Lowered by Cantor Fitzgerald

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Stock analysts at Cantor Fitzgerald cut their FY2025 EPS estimates for shares of Dianthus Therapeutics in a report released on Wednesday, May 14th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings of ($3.45) per share for the year, down from their previous estimate of ($3.16). The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share.

Several other brokerages also recently issued reports on DNTH. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Tuesday, May 13th. Robert W. Baird cut their price target on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an “outperform” rating for the company in a report on Tuesday, May 13th. Wedbush reissued an “outperform” rating and set a $36.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, Guggenheim reissued a “buy” rating and set a $84.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $53.00.

Dianthus Therapeutics Stock Performance

Shares of Dianthus Therapeutics stock opened at $19.69 on Friday. The firm’s 50-day simple moving average is $19.40 and its 200-day simple moving average is $22.11. Dianthus Therapeutics has a twelve month low of $13.37 and a twelve month high of $32.27. The firm has a market cap of $632.56 million, a P/E ratio of -7.88 and a beta of 1.48.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Monday, May 12th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The business had revenue of $1.16 million for the quarter, compared to analyst estimates of $0.81 million.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of institutional investors have recently modified their holdings of DNTH. SG Americas Securities LLC raised its stake in shares of Dianthus Therapeutics by 9.2% in the fourth quarter. SG Americas Securities LLC now owns 9,653 shares of the company’s stock worth $210,000 after acquiring an additional 814 shares during the last quarter. KBC Group NV bought a new position in shares of Dianthus Therapeutics in the fourth quarter worth about $35,000. R Squared Ltd bought a new position in shares of Dianthus Therapeutics in the fourth quarter worth about $26,000. Rhumbline Advisers raised its stake in shares of Dianthus Therapeutics by 3.8% in the fourth quarter. Rhumbline Advisers now owns 35,933 shares of the company’s stock worth $783,000 after acquiring an additional 1,316 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Dianthus Therapeutics by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 167,021 shares of the company’s stock worth $3,641,000 after acquiring an additional 1,092 shares during the last quarter. 47.53% of the stock is owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.